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Summary 
Background Neurodegeneration is the pathological substrate that causes major disability in secondary progressive 
multiple sclerosis. A synthesis of preclinical and clinical research identified three neuroprotective drugs acting on 
different axonal pathobiologies. We aimed to test the efficacy of these drugs in an efficient manner with respect to time, 
cost, and patient resource.
Methods We did a phase 2b, multiarm, parallel group, double-blind, randomised placebo-controlled trial at 
13 clinical neuroscience centres in the UK. We recruited patients (aged 25–65 years) with secondary progressive 
multiple sclerosis who were not on disease-modifying treatment and who had an Expanded Disability Status Scale 
(EDSS) score of 4·0–6·5. Participants were randomly assigned (1:1:1:1) at baseline, by a research nurse using a 
centralised web-based service, to receive twice-daily oral treatment of either amiloride 5 mg, fluoxetine 20 mg, riluzole 
50 mg, or placebo for 96 weeks. The randomisation procedure included minimisation based on sex, age, EDSS score 
at randomisation, and trial site. Capsules were identical in appearance to achieve masking. Patients, investigators, 
and MRI readers were unaware of treatment allocation. The primary outcome measure was volumetric MRI 
percentage brain volume change (PBVC) from baseline to 96 weeks, analysed using multiple regression, adjusting for 
baseline normalised brain volume and minimisation criteria. The primary analysis was a complete-case analysis 
based on the intention-to-treat population (all patients with data at week 96). This trial is registered with ClinicalTrials.
gov, NCT01910259.
Findings Between Jan 29, 2015, and June 22, 2016, 445 patients were randomly allocated amiloride (n=111), fluoxetine 
(n=111), riluzole (n=111), or placebo (n=112). The primary analysis included 393 patients who were allocated amiloride 
(n=99), fluoxetine (n=96), riluzole (n=99), and placebo (n=99). No difference was noted between any active treatment 
and placebo in PBVC (amiloride vs placebo, 0·0% [95% CI –0·4 to 0·5; p=0·99]; fluoxetine vs placebo –0·1% 
[–0·5 to 0·3; p=0·86]; riluzole vs placebo –0·1% [–0·6 to 0·3; p=0·77]). No emergent safety issues were reported. The 
incidence of serious adverse events was low and similar across study groups (ten [9%] patients in the amiloride group, 
seven [6%] in the fluoxetine group, 12 [11%] in the riluzole group, and 13 [12%] in the placebo group). The most 
common serious adverse events were infections and infestations. Three patients died during the study, from causes 
judged unrelated to active treatment; one patient assigned amiloride died from metastatic lung cancer, one patient 
assigned riluzole died from ischaemic heart disease and coronary artery thrombosis, and one patient assigned 
fluoxetine had a sudden death (primary cause) with multiple sclerosis and obesity listed as secondary causes.
Interpretation The absence of evidence for neuroprotection in this adequately powered trial indicates that exclusively 
targeting these aspects of axonal pathobiology in patients with secondary progressive multiple sclerosis is insufficient 
to mitigate neuroaxonal loss. These findings argue for investigation of different mechanistic targets and future 
consideration of combination treatment trials. This trial provides a template for future simultaneous testing of 
multiple disease-modifying medicines in neurological medicine.
Funding Efficacy and Mechanism Evaluation (EME) Programme, an MRC and NIHR partnership, UK Multiple 
Sclerosis Society, and US National Multiple Sclerosis Society.
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Introduction
Multiple sclerosis includes both inflammatory and neuro­
degener ative pathological mech anisms in the CNS. 
Neuro degenerative features form the dom inant substrate 
of progressive multiple sclerosis and manifest clinically by 
irreversible accumulation of disa bility.1 Progressive mult­
iple sclerosis is the major cause of disease­associated 
costs, both to individuals and health care systems2 and, 
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therefore, it is a key target for thera peutic development. 
However, by contrast with the range of treatments that 
mitigate inflammatory activity in relapsing­remitting 
multiple sclerosis, treat ments that can slow, stop, or 
reverse progressive multiple sclerosis are limited.
The diverse pathobiological mechanisms that contri bute 
to neuroaxonal loss in progressive multiple sclerosis 
provide a range of potential targets. Important proof­
of­concept findings have emerged for drugs that have anti­
inflammatory mechanisms of action, such as siponimod3 
and ocrelizumab.4 In parallel, evidence has been accumu­
lating for a range of candidate therapies that target key 
molecular processes in the axon itself, represent ing a more 
direct or downstream approach to achieve neuro protection. 
Over the past three decades, many negative trials have 
been published, with the findings attrib utable in part to 
suboptimum trial design.5 However, the fun damental 
question of whether direct targeting of axonal patho­
biological features can be an effective therapeutic strategy 
remains unanswered.
Research in context
Evidence before this study
We have previously published a systematic review and synthesis 
of available evidence for candidate oral neuroprotective drugs 
tested in clinical trials from patients with multiple sclerosis, 
dementia, motor neuron disease, Huntington’s disease, and 
Parkinson’s disease, combined with in-vivo data from 
experimental autoimmune encephalomyelitis (EAE) studies. 
We did two further searches in Ovid MEDLINE and Epub Ahead of 
Print, In-Process & Other Non-Indexed Citations and Daily 
(from 1946 to Feb 27, 2019), OVID Embase (from 1980 to 2019 
week 8), the Cochrane Database of Systematic Reviews, and the 
Cochrane Central Register of Controlled Trials (CENTRAL). 
In the first search, we used a combination of keywords and 
database-appropriate subject headings for the trial drugs: 
“amiloride” OR “fluoxetine” OR “riluzole” AND “multiple 
sclerosis” OR “experimental allergic encephalomyelitis” OR “EAE”. 
We excluded symptomatic human studies. We did not restrict our 
search by language. In the second search, we used a combination 
of keywords and database-appropriate subject headings for 
neurodegenerative neurological diseases, including “multiple 
sclerosis” OR “Parkinson’s disease” OR “amyotrophic lateral 
sclerosis-motor neuron disease” OR “Huntingdon’s disease” 
OR “dementia”, combined with terms to retrieve multiarm drug 
trials and the Cochrane Highly Sensitive Search Strategy for 
identifying randomised trials in MEDLINE (sensitivity and 
precision-maximising version, 2008 revision). We excluded 
symptomatic, dose-ranging, non-drug trials or studies of 
relapsing-remitting multiple sclerosis. We did not restrict our 
search by language. The first search retrieved five experimental 
studies for amiloride, indicating potential neuroprotection in 
animal models and human pathological samples. The most likely 
mechanism was blockage of ASIC1. In a clinical trial of primary 
progressive multiple sclerosis (n=14), a significant reduction was 
noted in the rate of whole-brain volume change with amiloride 
as well as improvements in deep grey and white matter tract 
diffusion indices. In three EAE studies, fluoxetine partly 
ameliorated paralysis and reduced inflammatory foci. Findings of 
two MR spectroscopy studies in humans showed an increase in 
N-acetylaspartate variables with fluoxetine, suggesting improved 
neuronal energetics and microstructural integrity by diffusion 
MRI, although a third study showed no change in markers of 
phosphocreatine metabolism. In a small placebo-controlled 
study, patients with relapsing multiple sclerosis treated with 
fluoxetine showed a trend towards a reduction in the number of 
new enhancing lesions over time. In a pilot study in progressive 
multiple sclerosis (n=42), non-significant benefits were seen in 
some markers of clinical progression with fluoxetine, although 
the study was underpowered. Riluzole reduced the severity of 
inflammation, demyelination, and axonal damage in a myelin 
oligodendrocyte glycoprotein-induced EAE system. In a run-in 
study in 16 patients with primary progressive multiple sclerosis, a 
reduction was noted in the rate of cervical atrophy and new 
T1 hypointense lesions with riluzole. In another study, no effect 
was seen on the atrophy rate in early multiple sclerosis with 
riluzole. The second search for multiarm drug trials in 
neurodegenerative diseases retrieved three studies. The first 
study in  patients with progressive multiple sclerosis (n=58) 
assessed cyclophosphamide, adrenocorticotropic hormone, and 
plasma exchange. In the second study, 782 patients with early 
Parkinson’s disease were randomly allocated to approved 
treatments (levodopa and DOPA decarboxylase inhibitor alone; 
levodopa, DOPA decarboxylase inhibitor, and selegiline; or 
bromocriptine). The third study was a three-arm trial of tianzhi 
granule, donepezil, or placebo in improving functional ability in 
vascular dementia. No other multiarm trials were retrieved by 
our search.
Added value of this study
In the MS-SMART trial, we chose three agents (amiloride, 
fluoxetine, and riluzole) to target different mechanistic pathways 
in patients with secondary progressive multiple sclerosis. 
We used a multiarm design to enable simultaneous assessment 
of these drugs at the important phase 2b decision point and, 
therefore, to accelerate the drug discovery process. The study 
design was robust with appropriate performance characteristics. 
We did not find any evidence of a neuroprotective effect of the 
three agents, despite positive early work in animals and humans.
Implications of all the available evidence
Multiarm trials are feasible and efficient in neurodegenerative 
diseases. They have the potential to examine promising 
experimental and early-phase agents in a timely fashion. 
The results of our study have implications for future 
experimental paradigms. This style of approach is necessary to 
accelerate treatment discovery in an area in which limited 
progress has been made.
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A further issue for adequate testing of an axonal­targeted 
neuroprotective strategy in people with prog ressive mul­
tiple sclerosis is the predictive value of drug selection 
from a large array of candidates. We did a systematic 
review and synthesis of available evidence for candidate 
oral neuroprotective drugs tested in clinical trials from 
patients with multiple sclerosis, dementia, motor neuron 
disease, Huntington’s disease, or Parkinson’s disease, 
combined with in­vivo data from experimental allergic 
enceph alitis (EAE) studies.6 This approach resulted 
in a shortlist of seven candidate drugs with different 
mechanisms of action that might prove beneficial in 
progressive multiple sclerosis: ibudilast, oxcarbazepine, 
pirfenidone, polyun saturated fatty acids (including lipoic 
acid), amiloride, fluoxetine, and riluzole. This strategy was 
ultimately confi rmed by positive phase 2 results for two of 
the drugs, ibudilast7 and lipoic acid.8
Based on our previous work,6 we aimed to test the 
efficacy of targeting axonal pathobiological features as a 
strategy to achieve neuroprotection in progressive mul tiple 
sclerosis. To maximise efficiency of testing and accelerate 
drug development, we used a multiarm approach that 
enabled simultaneous assess ment of several drugs at the 
important phase 2b decision point, a strategy that has been 
used successfully in oncology.9 Based on efficacy and drug 
supply, we selected three drugs from our candidate short­
list (amiloride, fluoxetine, and riluzole) for assessment 
against placebo.
Amiloride, widely used as a potassium­sparing diuretic, 
is an acid­sensing ion channel blocker.10,11 ASIC1 opens 
in response to inflammation­induced acidosis, causing 
sodium and calcium influxes.10 This action is associated 
with axonal injury in post­mortem studies of patients 
with acute multiple sclerosis,11 and blockade of ASIC1 with 
amiloride reduces axonal damage and improves clinical 
outcomes in rodent models.10 A pilot study in individuals 
with progressive multiple sclerosis showed a significant 
reduction in whole­brain atrophy.12 
Fluoxetine, a selective serotonin reuptake inhibitor used 
for depression, has pleiotropic neuroprotective effects 
stimu lating glycogenolysis and improving mitochondrial 
energy metabolism.13,14 In an underpowered negative trial, 
fluoxetine showed non­significant benefits in some mark­
ers of clinical progression.15 
Riluzole, licenced for motor neuron disease, reduces 
gluta mate release and antagonises voltage­dependent 
sodium channels.16 Glutamate excito toxicity results in neu­
ronal injury17 and its blockade in EAE reduces clinical 
impair ment and axonal damage.18–20 In a pilot study of rilu­
zole in people with progressive multiple sclerosis, a reduc­
tion in the rate of cervical cord atrophy and the number of 
new brain T1 hypointense lesions was rec orded,21 although 
findings of another study in individuals with early 
relapsing­remitting multiple sclerosis or clinical isolated 
syndrome did not show a reduction in the rate of atrophy.22 
The Multiple Sclerosis­Secondary Progressive Multi­
Arm Randomisation Trial (MS­SMART) is a phase 2b, 
multi centre, multiarm, parallel group, double­blind, ran­
dom ised placebo­controlled trial. We used the rate of brain 
atrophy to assess the putative neuroprotective effect of 
amiloride, fluoxetine, and riluzole in people with sec­
ondary progressive multiple sclerosis.23 Our aim was to 
efficiently test the efficacy of targeting axonal pathobiology 
as a strategy to achieve neuroprotection in progressive 
multiple sclerosis.
Methods 
Study design and participants
We did an investigator­led, multiarm, parallel group, 
double­blind, randomised placebo­controlled trial of amil­
or ide, fluoxetine, or riluzole versus placebo at 13 neuro ­
science centres in the UK. We screened patients for 
enrol ment and included those aged 25–65 years with a 
diagnosis of secondary progressive multiple sclerosis, 
confirmed as per usual clinical practice.24–26 
Major inclusion criteria were an Expanded Disability 
Status Scale (EDSS) score between 4·0 and 6·5, evidence 
of steady disability progression in the preceding 2 years 
(with either an increase of at least 1 point in EDSS score 
or a clinically documented increase in disability), and no 
concurrent use of disease­modifying therapies (standard 
UK practice for patients with secondary progressive 
multiple sclerosis). Patients were ineligible for the study 
if they had primary progressive multiple sclerosis, signifi­
cant depression (Beck’s Depression Index II score >19), 
major comorbidity, glaucoma, or epilepsy; were not able 
to undertake MRI; had a relapse or had been treated with 
corticosteroids within 3 months of screening; or used 
immunosuppressants, disease­modifying treatments, or 
experimental drugs within the previous 6 or 12 months 
(depending on the agent). Further details on the proto­
col, eligibility criteria, and study design are available 
elsewhere23 and in the appendix (pp 2–3). 
The study was done in accordance with the Declaration 
of Helsinki and International Council for Harmonisation 
Good Clinical Practice guidelines. Independent ethics 
approval for the protocol was granted by REC 13/SS/0007, 
and all patients provided written informed consent before 
entering the study. Safety oversight was the respons­
ibility of the Data Monitoring Committee, which reviewed 
accruing participant­level data every 6 months. Individual 
site medical monitoring was also mandated.
Randomisation and masking
Within 30 days after screening for enrolment to the study, 
we randomly allocated patients (1:1:1:1) at base line either 
amiloride, fluoxetine, riluzole, or placebo. A research 
nurse used a centralised web­based service pro vided by the 
Edinburgh Clinical Trials Unit (Usher Institute, University 
of Edinburgh, Edinburgh, UK) to randomly assign inter­
ventions, with mini mis ation by sex, age (<45 years vs 
≥45 years), EDSS score at randomisation (4·0–5·5 vs 
6·0–6·5), and trial site. The mini misation procedure 
incor p orated a random ele ment whereby the assigned 
See Online for appendix
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treatment was switched with a probability of 10% from the 
group that would give greatest balance to one of the other 
three study groups (with a probability of 3·33% for each of 
the other study groups). Amiloride, fluoxetine, riluzole, 
and placebo capsules were over­encapsulated and identical 
in appearance. Patients and investigators, including MRI 
analysts, treating clini cians, and inde pendent assessing 
neurologists were unaware of treat ment allocations and 
had no access to randomisa tion codes. We asked patients 
and clinicians to complete a questionnaire at week 96 to 
assess the validity of the masking procedures.
Procedures
We initially administered assigned treatments orally once 
daily, from baseline (week 0) for 4 weeks, then patients 
received doses twice daily from week 4 until week 96. 
Doses were amiloride hydrochloride 5 mg, fluoxetine 
20 mg, riluzole 50 mg, or matching placebo. After the 
baseline visit, patients were seen at weeks 4, 8, 12, 24, 36, 
48, 72, and 96, with a final safety telephone call at week 100. 
Brain MRI was done at screening for enrolment, week 24, 
and week 96. Neurological assess ments were done at 
screening, baseline, week 48, and week 96. Safety blood 
tests were assessed at every study visit and included full 
blood count, electrolytes, and liver and renal function tests. 
Study treatment was discon tinued if confirmed repeat 
meas urements showed the following blood test concen­
trations: potassium less than 2·8 mmol/L or more than 
5·5 mmol/L; sodium less than 125 mmol/L; alanine amino­
transferase, aspar tate amino transferase, or γ­glutamyl 
trans ferase more than five times the upper limit of normal; 
creatinine more than 130 μmol/L; neutrophil count 
less than 1·0 × 10⁹ cells per L, platelet count less than 
50 × 10⁹ cells per L; or haemoglobin less than 80 g/L. Adverse 
events were assessed at every study visit.
Outcomes
The primary endpoint was the percentage brain volume 
change (PBVC) between baseline and 96 weeks, which 
is the standard primary outcome in phase 2 trials in pro­
gressive multiple sclerosis. We used the Structural Image 
Evaluation using Normalization of Atrophy (SIENA) 
method.27,28 SIENA is an automated method that registers 
the follow­up scan to the baseline scan and produces an 
integral of the edge motion occurring in each voxel between 
scans and directly calculates the PBVC from those values.
MRI secondary endpoints were counts of new or enlarg­
ing T2 lesions at 96 weeks and PBVC at 24 weeks. The core 
MRI protocol included fluid­attenuated inver sion recovery 
(FLAIR), proton density, and T2 and volu metric T1­weighted 
Figure 1: Trial profile
*All patients lost to follow-up at any time during active follow-up (ie, up to and including the 100-week telephone call). Two patients withdrew after the 96-week 
MRI scan but before the end of the study (one allocated riluzole and one allocated placebo) and were included in the primary analysis. Two patients allocated riluzole 
also received fluoxetine prescribed by their family doctor towards the end of the trial. One patient allocated riluzole was withdrawn by a clinician: all other withdrawals 
were the patient’s decision.
547 assessed for eligibility
445 randomised
102 excluded
 90 ineligible
           6 withdrawn by clinician
           3 declined to participate
           3 other reasons
111 allocated amiloride
99 included in primary analysis
 12 excluded from primary 
       analysis 
 2 withdrawn before 96-week 
 MRI scan 
 1 died 
 3 unable to contact
 4 MRI scan not done
 2 image quality issue
6 lost to follow-up*
 2 withdrawn
 1 died 
 3 unable to contact
111 allocated fluoxetine
96 included in primary analysis
 15 excluded from primary 
       analysis 
 4 withdrawn before 96-week 
 MRI scan 
 1 died 
 4 unable to contact
 4 MRI scan not done
 2 image quality issue
9 lost to follow-up*
 4 withdrawn
 1 died 
 4 unable to contact
111 allocated riluzole
99 included in primary analysis
 12 excluded from primary 
       analysis 
 6 withdrawn before 96-week 
 MRI scan 
 1 died 
 2 unable to contact
 2 MRI scan not done
 1 image quality issue
10 lost to follow-up*
 7 withdrawn
 1 died 
 2 unable to contact
112 allocated placebo
99 included in primary analysis
 13 excluded from primary 
       analysis 
 2 withdrawn before 96-week 
 MRI scan 
 4 unable to contact
 6 MRI scan not done
 1 scanner issue
7 lost to follow-up*
 3 withdrawn
 4 unable to contact
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scans, as previously described.23 MRI data were analysed 
independently at a central read ing site (Queen Square 
Multiple Sclerosis Centre, University College London, 
London, UK). Clinical secondary end points were changes 
from baseline to weeks 48 and 96 in EDSS score, the Timed 
25­Foot Walk, the 9­Hole Peg Test, the Paced Auditory 
Serial Addition Test, the Multiple Sclerosis Functional 
Composite score, the Symbol Digit Modalities Test, high 
contrast (100%) visual acuity, and Sloan low contrast visual 
acuity (contrast 5%, 2·5%, and 1·25%). 
Time to first relapse was recorded. Patient­reported 
outcomes were also measured at baseline, week 48, and 
week 96 using: the Multiple Sclerosis Impact Scale 29 
items version 2; the Multiple Sclerosis Walking Scale 
version 2; the Neurological Fatigue Index; and health­
related quality­of­life (measured with EuroQol five dim­
ensions five levels [EQ­5D­5L]). Neuropathic pain scores 
were also obtained and will be reported separately. The 
Multiple Sclerosis Functional Composite Z­score was 
norm alised (signed square­root transformed) using partici­
pants’ baseline scores. 
Statistical analysis
The sample size calculation for the trial was based on a 
study from Altmann and colleagues.29 The percentage of 
expected total cohort dropouts was based on two phase 2 
studies in secondary progressive multiple sclerosis,30,31 
from which we calculated that including 110 patients per 
Amiloride (n=111) Fluoxetine (n=111) Riluzole (n=111) Placebo (n=112) Total (n=445)
Age (years) 55·2 (49·0–60·5) 55·5 (50·7–60·2) 55·1 (49·7–59·2) 56·4 (49·2–60·4) 55·5 (49·7–60·3)
Male sex 36 (32%) 37 (33%) 37 (33%) 37 (33%) 147 (33%)
Female sex 75 (68%) 74 (67%) 74 (67%) 75 (67%) 298 (67%)
Expanded Disability Status Scale score 6·0 (5·5–6·5) 6·0 (5·5–6·5) 6·0 (5·5–6·5) 6·0 (5·5–6·5) 6·0 (5·5–6·5)
Time since first symptoms (years) 20 (13–30) 21 (16–29) 21 (16–26) 19 (13–29) 21 (15–29)
Time since progression (years) 6 (4–11) 5 (3–10) 6 (4–10) 5 (3–10) 6 (3–10)
Beck Depression Index II score 6 (4–9) 6 (3–10) 7 (4–12) 7 (4–12) 6 (4–11)
Multiple Sclerosis Functional Composite 
score (Z-score) 
–0·19 (1·19) –0·02 (0·60) –0·09 (0·95) –0·00 (0·91) –0·07 (0·93)
Paced Auditory Serial Addition Test 39·0 (13·7) 36·6 (15·2) 36·9 (16·0) 41·5 (13·9) 38·5 (14·8)
Timed 25-Foot Walk (s) 12·0 (8·0–23·0) 11·0 (8·5–18·0) 11·4 (8·6–18·4) 10·6 (7·8–15·0) 11·2 (8·4–18·6)
9-Hole Peg Test (s–1) 0·03 (0·01) 0·03 (0·01) 0·03 (0·01) 0·03 (0·01) 0·03 (0·01)
Symbol Digit Modalities Test 43·9 (12·4) 44·1 (11·4) 44·5 (13·1) 44·1 (12·8) 44·2 (12·4)
High contrast (100%) visual acuity 50·1 (11·2) 50·8 (10·8) 48·5 (14·8) 50·4 (12·7) 49·9 (12·5)
Sloan low contrast visual acuity
5% contrast 32·6 (13·4) 32·9 (12·8) 30·0 (16·1) 33·9 (14·6) 32·4 (14·3)
2·5% contrast 19·1 (12·7) 17·6 (12·4) 18·8 (14·2) 20·8 (14·0) 19·1 (13·3)
1·25% contrast 8·2 (10·7) 6·9 (9·6) 7·1 (10·7) 9·9 (11·9) 8·0 (10·8)
Multiple Sclerosis Impact Scale 29 items version 2
Total score 63·9 (13·4) 65·0 (13·8) 69·2 (15·0) 66·1 (14·4) 66·0 (14·3)
Physical score 48·0 (10·5) 48·3 (10·4) 51·0 (11·3) 49·0 (11·2) 49·1 (10·9)
Psychological score 15·9 (4·5) 16·7 (4·8) 18·2 (5·4) 17·1 (5·0) 17·0 (5·0)
Multiple Sclerosis Walking Scale version 2 41·4 (9·2) 41·1 (9·8) 42·6 (9·3) 41·6 (9·9) 41·7 (9·5)
Neurological Fatigue Index
Summary score 18·0 (4·2) 17·4 (3·9) 19·1 (4·8) 17·8 (3·9) 18·1 (4·2)
Physical score 15·1 (3·8) 14·7 (3·9) 15·9 (4·3) 14·7 (3·7) 15·1 (3·9)
Cognitive score 6·5 (2·2) 6·2 (2·2) 7·1 (2·3) 6·3 (2·4) 6·5 (2·3)
Diurnal score 10·1 (2·8) 9·6 (2·9) 10·2 (3·1) 9·7 (2·5) 9·9 (2·8)
Nocturnal score 7·7 (2·0) 7·6 (2·5) 8·2 (2·8) 8·0 (2·3) 7·9 (2·4)
EQ-5D-5L
Index score 0·68 (0·17) 0·70 (0·16) 0·66 (0·17) 0·67 (0·18) 0·68 (0·17)
VAS score 66·1 (16·9) 67·5 (19·5) 61·7 (21·0) 65·2 (20·3) 65·2 (19·5)
At least one relapse in past 2 years 15 (14%) 9 (8%) 6 (5%) 12 (11%) 42 (9%)
Baseline normalised brain volume (mL) 1432·2 (84·2) 1413·1 (82·4) 1414·2 (74·8) 1431·0 (91·1) 1422·6 (83·6)
T2 lesion volume (mL) 10·1 (3·5–17·4) 10·7 (4·8–20·4) 10·5 (3·8–19·6) 10·6 (4·4–17·6) 10·4 (4·1–18·6)
Data presented are n (%), mean (SD), or median (IQR). No data were missing for the 9-Hole Peg Test, Multiple Sclerosis Impact Scale 29 items version 2, and EQ-5D-5L 
(VAS score); for the remaining variables, varying amounts of data were missing up to a maximum of 12 patients overall (maximum five for amiloride, two for fluoxetine, 
three for riluzole, and four for placebo). EQ-5D-5L=EuroQol five dimensions five levels. VAS=visual analogue scale.
Table 1: Baseline characteristics of randomised participants
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study group would provide 90% statistical power in the 
analysis of covariance to detect a 40% reduction in PBVC 
versus placebo, allowing for 10% dropouts plus 10% of 
participants discontinuing treatment while remaining in 
follow­up. 
Baseline data were described by summary statistics. 
A multiple regression model was fitted to the PBVC 
outcome variable, with study group as an explan atory 
factor (using placebo as the reference cate gory), adjust­
ing for baseline normalised brain volume and the 
minimis ation variables (age, sex, treatment centre, and 
EDSS score at randomisation). The multicentre trial 
design was taken into account by adjusting for treatment 
centre as a fixed effect. For each pairwise compari­
son of active treatment versus control, we calculated 
the mean difference in PBVC. Additionally, we used the 
method of Dunnett to adjust 95% simul taneous CIs,32 to 
allow for multiple pairwise comparisons to a common 
con trol group and maintain the overall family­wise error 
rate below 5%. Dunnett­adjusted p values are rep­
orted for the primary outcome analyses.33,34 The prim­
ary analysis was a complete­case analysis based on 
the intention­to­treat population. The intention­to­treat 
popu lation included all patients in the MS­SMART trial 
who underwent randomisation and had data avail able at 
week 96.
The effects of missing data or outliers on the primary 
outcome findings were investigated by doing three sensi­
tivity analyses. These entailed excluding outliers more 
than 4 SD away from the mean, imputing missing data 
using a standard multiple imputation method, and 
imputing missing data under a missing­not­at­random 
assump tion, whereby a constant value was added to the 
values imputed using multiple imputation equal to 
the observed SD in the primary outcome at 96 weeks.
A further primary outcome analysis was done in the 
per­protocol population, which included participants who 
were adherent to the protocol and compliant with the 
originally assigned treatment throughout the duration of 
follow­up. Patients were judged compliant with the 
assigned treat ment if they reported taking, on average, 
90% or more of their prescribed medication (taking 
account of planned down­titrations and deferred up­
titrations) in the 30 days preceding every clinic visit.
Secondary outcome analyses were not adjusted for 
multiple comparisons and used 5% as the nominal signifi­
cance level. The number of new or enlarging T2 lesions 
detected at the 96­week MRI scan was compared between 
each of the three active treatment groups and placebo by 
means of an overdispersed Poisson regression model 
fitted to the number of new or enlarging T2 lesions at 
96 weeks, with adjustment for minimisation variables.
For continuous or ordinal outcomes measured at 
96 weeks (ie, the EDSS score, the 9­Hole Peg Test, the 
Paced Auditory Serial Addition Test, the Multiple Sclerosis 
Functional Composite score, the Symbol Digit Modalities 
Test, Sloan low contrast visual acuity, the Multiple Sclerosis 
Impact Scale 29 items version 2, the Multiple Sclerosis 
Walking Scale version 2, the Neurological Fatigue Index, 
and health­related quality of life), we used a multiple linear 
Figure 2: Primary outcome
Boxplots of PBVC by study group at 24 weeks (A) and 96 weeks (B). Horizontal lines are median and IQR; whiskers extend to the minimum and maximum within 1·5 times the IQR; outliers are shown 
as individual points. Mean PBVC by study group (C), for patients with PBVC data at both 24 and 96 weeks (n=374); whiskers are SD. PBVC=percentage brain volume change.
Normalised brain 
volume at baseline 
(mL)
PBVC at 96 weeks* Adjusted mean 
difference in PBVC vs 
placebo (95% CI)†
p value†
Amiloride (n=99) 1426·9 (82·4) –1·3% (1·0) 0·0% (–0·4 to 0·5) 0·99
Fluoxetine (n=96) 1414·9 (79·9) –1·4% (1·5) –0·1% (–0·5 to 0·3) 0·86
Riluzole (n=99) 1416·0 (75·0) –1·4% (1·5) –0·1% (–0·6 to 0·3) 0·77
Placebo (n=99) 1428·8 (91·5) –1·3% (1·1) ·· ··
Data are mean (SD) unless otherwise stated. PBVC=percentage brain volume change. *Negative values indicate 
reductions in brain volume. †Adjusted for minimisation variables (age, sex, study centre, and EDSS score at 
randomisation) and baseline normalised brain volume, and accounted for multiple testing versus a common control 
group using Dunnett’s method.
Table 2: Primary outcome analysis of PBVC at 96 weeks, intention-to-treat population
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Amiloride 
(n=102)
Fluoxetine 
(n=97)
Riluzole 
(n=96)
Placebo 
(n=98)
Amiloride vs placebo Fluoxetine vs placebo Riluzole vs placebo
Adjusted mean 
difference 
(95% CI)*
p value Adjusted mean 
difference 
(95% CI)*
p value Adjusted mean 
difference 
(95% CI)*
p value
Expanded Disability Status Scale 
score†
6·0 (1·0) 5·9 (1·2) 6·0 (1·1) 6·0 (1·1) 0·1 
(–0·1 to 0·2)
0·61 –0·1 
(–0·3 to 0·2)
0·54 0·1 
(–0·2 to 0·2)
0·63
Multiple Sclerosis Functional 
Composite score (Z-score)‡
–0·55 (1·87) –0·53 (1·66) –0·47 (1·69) –0·41 (1·78) 0·06 
(–0·15 to 0·27)
0·59 –0·09 
(–0·30 to 0·12)
0·42 0·02 
(–0·19 to 0·23)
0·84
Paced Auditory Serial Addition 
Test
41·1 (14·3) 36·8 (16·3) 38·4 (15·6) 41·9 (16·7) 0·9 
(–1·9 to 3·7)
0·51 –1·1 
(–3·9 to 1·8)
0·47 0·4 
(–2·4 to 3·3)
0·76
9-Hole Peg Test (s–1) 0·03 (0·01) 0·03 (0·01) 0·03 (0·01) 0·03 (0·01) 0·00 
(–0·00 to 0·00)
0·36 0·00 
(–0·00 to 0·00)
0·85 0·00 
(–0·00 to 0·00)
0·27
Symbol Digit Modalities Test 43·0 (14·9) 44·8 (13·7) 44·9 (14·2) 46·1 (14·5) –1·0 
(–3·1 to 1·0)
0·32 –1·1 
(–3·2 to 0·9)
0·29 –0·8 
(–2·9 to 1·3)
0·44
High contrast (100%) visual 
acuity
50·1 (10·9) 50·5 (11·2) 47·8 (15·8) 49·1 (13·7) 3·0  
(0·5 to 5·6)
0·020 1·8  
(–0·7 to 4·4)
0·16 1·6 
(–1·0 to 4·2)
0·22
Sloan low contrast visual acuity
5% contrast 31·8 (12·9) 32·6 (13·1) 31·2 (15·6) 32·4 (13·5) 1·0 
(–1·8 to 3·8)
0·49 1·3  
(–1·6 to 4·1)
0·38 1·5 
(–1·4 to 4·3)
0·32
2·5% contrast 17·1 (14·2) 16·5 (13·2) 17·7 (14·2) 18·1 (13·4) 0·9 
(–2·0 to 3·7)
0·55 1·3  
(–1·5 to 4·1)
0·37 1·7 
(–1·2 to 4·6)
0·25
1·25% contrast 5·2 (8·8) 4·0 (8·2) 6·1 (10·4) 6·8 (9·7) –0·6 
(–2·7 to 1·5)
0·58 –0·8 
(–2·9 to 1·3)
0·46 0·7 
(–1·4 to 2·9)
0·49
Multiple Sclerosis Impact Scale 29 items version 2
Total score 72·3 (16·3) 69·7 (15·1) 72·9 (15·8) 69·5 (17·2) 3·7  
(0·2 to 7·2)
0·037 0·5  
(–3·0 to 4·0)
0·79 0·9 
(–2·6 to 4·5)
0·60
Physical score 53·2 (12·0) 52·1 (11·4) 53·6 (12·4) 51·3 (12·7) 2·2 
(–0·3 to 4·7)
0·089 0·7  
(–1·8 to 3·3)
0·57 0·6 
(–2·0 to 3·1)
0·66
Psychological score 19·1 (6·1) 17·7 (5·3) 19·3 (5·4) 18·3 (5·8) 1·5  
(0·2 to 2·8)
0·025 –0·3 
(–1·6 to 1·0)
0·68 0·5 
(–0·9 to 1·8)
0·49
Multiple Sclerosis Walking Scale 
version 2
44·2 (9·4) 44·4 (8·8) 44·6 (9·6) 43·6 (10·1) 0·5 
(–1·6 to 2·5)
0·66 1·0  
(–1·1 to 3·1)
0·35 0·6 
(–1·5 to 2·8)
0·55
Neurological Fatigue Index
Summary score 19·4 (5·3) 18·3 (4·0) 19·7 (4·8) 18·3 (5·5) 0·9 
(–0·2 to 2·0)
0·11 0·5  
(–0·6 to 1·7)
0·36 0·7 
(–0·4 to 1·9)
0·20
Physical score 16·3 (4·5) 15·4 (3·8) 16·4 (4·2) 15·0 (4·8) 1·2  
(0·2 to 2·3)
0·019 0·7  
(–0·3 to 1·8)
0·17 1·0 
(–0·0 to 2·1)
0·061
Cognitive score 7·1 (2·5) 6·7 (2·1) 7·4 (2·1) 6·8 (2·9) 0·1 
(–0·4 to 0·6)
0·70 0·2  
(–0·4 to 0·7)
0·55 0·2 
(–0·4 to 0·7)
0·55
Diurnal score 10·7 (3·2) 10·3 (2·9) 10·7 (2·5) 10·6 (2·6) –0·3 
(–0·9 to 0·3)
0·36 –0·3 
(–1·0 to 0·3)
0·29 –0·3 
(–0·9 to 0·4)
0·40
Nocturnal score 8·7 (2·1) 8·3 (2·3) 8·4 (2·5) 8·2 (2·2) 0·6  
(0·1 to 1·1)
0·013 0·4  
(–0·1 to 0·9)
0·12 0·1 
(–0·4 to 0·6)
0·65
EQ-5D-5L
Index score 0·60 (0·23) 0·62 (0·21) 0·60 (0·19) 0·61 (0·22) –0·01 
(–0·06 to 0·04)
0·69 –0·02 
(–0·06 to 0·03)
0·52 –0·01 
(–0·05 to 0·04)
0·82
VAS score 66·1 (16·9) 67·5 (19·5) 61·7 (21·0) 65·2 (20·3) –2·1 
(–7·6 to 3·5)
0·47 –3·0 
(–8·6 to 2·6)
0·29 –3·0 
(–8·6 to 2·7)
0·30
New or enlarging T2 lesions 3·7 (8·1) 1·8 (5·3) 2·8 (5·7) 3·0 (6·9) 1·2  
(0·8 to 1·8)
0·29 0·5  
(0·3 to 0·9)
0·012 1·0  
(0·6 to 1·5)
0·81
Data are mean (SD). Results are derived from a model analysing data for 393 participants who had at least some 96-week outcome data. Numbers of patients are the maximum per group; the minimum 
sample size was n=380 for each secondary outcome (minimum per group: amiloride, n=98; fluoxetine, n=94; riluzole, n=92; placebo, n=94). The multiple regression model for each outcome included 
randomised treatment as an explanatory factor variable (with placebo as the reference category), the baseline measurement, and minimisation variables (age, sex, treatment centre, and Expanded Disability 
Status Scale score at baseline). EQ-5D-5L=EuroQol five dimensions five levels. VAS=visual analogue scale. *Effect sizes are adjusted mean difference (95% CI), except for new or enlarging T2 lesions, which is the 
adjusted rate ratio (investigational drug:placebo) and 95% CI. †95% CIs calculated using 1000 bootstrap resamples. ‡The Multiple Sclerosis Functional Composite score was signed square-root transformed 
before analysis.
Table 3: Secondary outcomes at 96 weeks
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regression method to calculate adjusted mean differences 
and 95% CIs for the individual comparisons between each 
active treatment and placebo. Regression models were 
adjusted for baseline and the minimisation variables. 
For the EDSS outcome only, 95% CIs were calculated 
using a bootstrap method due to the ordinal nature of 
the out come variable. Cox proportional­hazard models 
adjusting for the minimisation variables were used for 
time­to­first relapse and the Timed 25­Foot Walk test at 
96 weeks. Analyses were done using SAS version 9.4 (SAS 
Institute, Cary, NC, USA). 
This trial is registered with ClinicalTrials.gov, 
NCT01910259.
Role of the funding source
The funder had no role in study design, data collection, 
data analysis, data interpretation, or writing of the report. 
The corresponding author had full access to all data in 
the study and had final responsibility for the decision to 
submit for publication.
Results
The study began in December, 2014, and ended in July, 2018. 
We screened 547 individuals for enrolment to the study, of 
whom 102 were judged ineligible or dec lined to partici­
pate (figure 1). Between Jan 29, 2015, and June 22, 2016, we 
randomly allocated 445 patients with secondary progress­
ive multiple sclerosis either amiloride (n=111), fluoxetine 
(n=111), riluzole (n=111), or placebo (n=112). Baseline demo­
graphic characteristics were compar able between study 
groups, including whole­brain and T2 lesion volumes 
(table 1). The percentage loss to follow­up was 5–9% across 
study groups. Primary out come data at 96 weeks were 
available for 393 (88%) of 445 participants, 99 of whom 
were assigned amiloride, 96 fluoxetine, 99 riluzole, and 
99 placebo.
Figure 2 shows the primary outcome of PBVC at 
96 weeks. The adjusted mean PBVC did not differ between 
each active treatment and placebo (table 2). Findings of 
sensitivity analyses accorded with the primary analysis 
results (appendix p 4).
At 96 weeks, the mean number of new or enlarging 
T2 lesions in patients assigned placebo was 3·0 (SD 6·9; 
median 0 [IQR 0–2]). Compared with placebo, a similar 
number of new or enlarging T2 lesions were detected at 
the 96­week MRI scan for amiloride (rate ratio [RR] 1·2, 
95% CI 0·8–1·8; p=0·29) and for riluzole (1·0, 0·6–1·5; 
p=0·81). Fluoxetine had fewer new or enlarging T2 lesions 
compared with placebo (RR 0·5, 95% CI 0·3–0·9; 
p=0·012). 
The PBVC at 24 weeks was greater for patients assigned 
fluoxetine than for those allocated placebo (adjusted mean 
difference –0·31, 95% simultaneous CI –0·60 to –0·02; 
Dunnet­adjusted p=0·032), but not for the other active 
treatment groups versus placebo. No difference was noted 
between active treatment groups and placebo for PBVC 
between 24 weeks and 96 weeks (appendix p 4). Secondary 
outcomes accord with insufficient evidence of therapeutic 
effect (table 3). Although five of 60 clinician­reported and 
patient­reported outcome comparisons against placebo 
were significant (p<0·05), this finding is similar to what 
we would expect due to random chance when testing all 
60 comparisons each at the 5% significance level.
51 (11%) of 445 patients had at least one relapse during 
the study, with 16 (14%) having a relapse in the amiloride 
group, ten (9%) in the fluoxetine group, 11 (10%) in the 
riluzole group, and 14 (12%) in the placebo group. 
Compared with placebo, time to first relapse did not differ 
for amiloride (hazard ratio [HR] 1·14, 95% CI 0·56–2·35), 
fluoxetine (0·74, 0·33–1·66), or riluzole (0·78, 0·35–1·73). 
Similarly, compared with placebo, the Timed 25­Foot 
Walk test did not differ for amiloride (HR 0·82, 95% CI 
0·61–1·12), fluoxetine (0·81, 0·59–1·10), or riluzole (0·84, 
0·61–1·13).
Findings of the clinician and patient masking question­
naire indicated that treatment assignments had been 
masked successfully: 51% of patients and 59% of clini­
cians who made a guess regarding active treatment or 
placebo status were correct (κ=0·04, 95% CI –0·06 to 0·14; 
and κ=0·13, –0·01 to 0·26; respectively). Secondary out­
comes at 48 weeks are reported in the appendix (pp 11–12). 
Concomitant drugs taken throughout the duration of the 
trial are listed in the appendix (p 13).
Our study population showed deterioration in several 
outcomes over the 96­week period (appendix pp 5–10). For 
example, in the placebo group, little change was noted 
between baseline and week 96 in the Paced Auditory Serial 
Addition Test, the 9­Hole Peg Test, the Symbol Digit 
Modalities Test, high contrast (100%) visual acuity, and 
Sloan low contrast visual acuity (contrast 5%), but 
Figure 3: Stacked bar chart for change in EDSS score from randomisation to 96 weeks
Positive change is worsening in EDSS score and negative change is improvement in EDSS score. EDSS=Expanded 
Disability Status Scale. 
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substantial changes were seen in EDSS scores (figure 3), 
the Timed 25­Foot Walk, and Sloan low­contrast visual 
acuity (contrast 1·25%).
No emergent safety issues were recorded with the active 
treatments. Adverse and serious adverse events are shown 
in table 4 and in the appendix (pp 14, 15). Three deaths 
occurred during the study, which were judged by the Data 
Monitoring Committee unrelated to allocated treatments. 
One patient assigned amiloride died from metastatic lung 
cancer, one patient assigned riluzole died from ischaemic 
heart disease and coronary artery thrombosis, and one 
patient assigned fluoxetine had a sudden death (primary 
cause) with secondary causes of death listed as multiple 
sclerosis and obesity in the coroner’s report.
Discussion
The findings of MS­SMART, a large, multicentre, multi­
arm randomised trial in patients with secondary prog r es­
sive multiple sclerosis, showed that none of the three study 
drugs (amiloride, fluoxetine, and riluzole) had any effect 
on the primary outcome of PBVC over 96 weeks or any 
second ary outcomes, compared with placebo. Significant 
effi ciency gains with respect to the study des ign were, 
however, seen in terms of people, time, and eco nomic 
resources. The study cohort was typical of patients with 
non­relapsing secondary progressive multiple sclerosis, 
with a median disease duration of 21 years (IQR 15–29), 
median secondary progression of 6 years (3–10), use of 
unilateral support when walking (median EDSS score 
6·0 [5·5–6·5]), and more than 90% of patients were 
relapse­free for at least 2 years before recruit ment. High 
levels of retention (>90%) and adherence were reported, 
and on­trial behaviour was also typical of patients with 
non­relapsing second ary progressive multiple sclerosis, 
with low levels of inflammatory disease activity clinically 
(11% of patients had an on­study relapse) and radio logically 
(mean number of new or enlarging lesions was 3·0 [SD 6·9], 
median 0 [IQR 0–2]). Clear radio logical progression was 
seen, with PBVC of roughly –0·7% per year. 
Taken together with the effectiveness of our trial 
masking and the meeting of all previous assumptions 
underlying our power calculations, MS­SMART was 
sensitive to detect any neuroprotective effect of the three 
drugs tested. Some data were missing, 12% for the 
Amiloride (n=111) Fluoxetine (n=111) Riluzole (n=109) Placebo (n=112)
Adverse events (n) 609 738 634 582
Patients experiencing at least one adverse event 100 (90%) 105 (95%) 101 (93%) 103 (92%)
Cardiac disorders 1 (1%) 3 (3%) 8 (7%) 2 (2%)
Eye disorders 13 (12%) 8 (7%) 9 (8%) 8 (7%)
Gastrointestinal disorders 46 (41%) 62 (56%) 49 (45%) 36 (32%)
General disorders and administration 26 (23%) 28 (25%) 27 (25%) 32 (29%)
Infections and infestations 68 (61%) 58 (52%) 62 (57%) 69 (62%)
Injury, poisoning, and procedural complications 26 (23%) 43 (39%) 29 (27%) 28 (25%)
Investigations* 10 (9%) 20 (18%) 17 (16%) 8 (7%)
Metabolism and nutrition disorders 2 (2%) 9 (8%) 7 (6%) 4 (4%)
Musculoskeletal and connective tissue disorders 37 (33%) 26 (23%) 37 (34%) 29 (26%)
Nervous system disorders 48 (43%) 46 (41%) 47 (43%) 44 (39%)
Psychiatric disorders 21 (19%) 30 (27%) 22 (20%) 22 (20%)
Renal and urinary disorders 9 (8%) 13 (12%) 10 (9%) 5 (4%)
Respiratory disorders 15 (14%) 23 (21%) 13 (12%) 16 (14%)
Skin and subcutaneous tissue disorders 16 (14%) 11 (10%) 13 (12%) 17 (15%)
Surgical and medical procedures 6 (5%) 3 (3%) 8 (7%) 7 (6%)
Vascular disorders 4 (4%) 2 (2%) 3 (3%) 6 (5%)
Patients experiencing at least one serious adverse event 10 (9%) 7 (6%) 12 (11%) 13 (12%)
Infections and infestations 4 (4%) 1 (1%) 4 (4%) 4 (4%)
Injury, poisoning, and procedural complications 3 (3%) 0 (0%) 3 (3%) 2 (2%)
Patients experiencing at least one suspected unexplained 
serious adverse reaction
0 (0%) 0 (0%) 1 (1%) 0 (0%)
Data are number of patients experiencing each type of event (% of cohort). Adverse events occurring in at least 5% of patients in any study group are shown. Serious adverse 
events occurring in at least 3% of patients in any group are shown. Full data are provided in the appendix (pp 14–15). The safety population comprised all patients who 
underwent randomisation, excluding two patients allocated riluzole who were prescribed fluoxetine by their family doctor towards the end of the trial (protocol deviation); 
these patients had five adverse events and no serious adverse events; a few of the adverse events occurred after fluoxetine was prescribed and, therefore, might be 
attributable to fluoxetine rather than riluzole (or a combination of the two). Progressive change due to secondary progressive multiple sclerosis in motor, sensory, balance, 
sphincter (including urinary tract infections), vision, cognitive, and fatigue levels were not reported as adverse events, serious adverse events, or suspected unexplained 
serious adverse reactions. Relapses were not reported as adverse events, serious adverse events, or suspected unexplained serious adverse reactions but are collated 
separately. *For example, abnormal blood results or weight loss.
Table 4: Adverse events, safety population
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primary endpoint and as high as 15% for some secondary 
endpoints; although this shortfall brings some potential 
for bias, sensitivity analyses were supportive of the 
findings of the primary analysis.
Drug selection in our study was based on findings of two 
separate systematic reviews:6 first, we looked at preclinical 
studies of demyelination, inflammation, axonal loss, and 
neurobehavioural changes in EAE models of multiple 
sclerosis; second, we assessed clinical evidence at phase 2a 
in patients with multiple sclerosis and other neuro­
degenerative disorders that share common pathways of 
neurodegeneration. We did not select agents with clinically 
significant safety profile issues, those most likely to 
produce only symptomatic benefit, drugs with an immuno­
suppressive mechanism of action, agents with limited 
efficacy data or biological plausibility, and those that had 
been assessed previously in patients with relapsing­
remitting multiple sclerosis. 
After initial identification of 120 potential candidates, 
two further important review steps led us to identify 
seven drugs for analysis: ibudilast, oxcarbazepine, 
pirfenidone, polyunsaturated fatty acids (including lipoic 
acid), amiloride, fluoxetine, and riluzole. Ibudilast and 
lipoic acid have now shown phase 2 success, confirming 
the predictive value of our candidate selection method­
ology.7,8 Pharmacokinetic considerations (eg, limited bio­
avail ability in the CNS) are also of potential relevance to 
the results of our trial. However, riluzole and fluoxetine 
have known CNS effects at the doses used and are 
established drugs for treatment of motor neuron disease 
and dep ression, respectively. Amiloride has a primary 
non­CNS target; however, the dose used was based on an 
earlier phase 2a trial.
The mechanisms of action of the three drugs we tested 
(accepting that there are likely to be additional off­target 
effects of these drugs) mainly target distinct possible 
axonal pathobiological features implicated in the neuro­
degenerative substrate of progressive multiple sclerosis. 
Amiloride blocks acid­sensing ion channels and, there­
fore, targets axonal calcium overload; riluzole targets 
glutamate­mediated excitotoxic injury; and fluox etine 
stimulates astrocytic lactate release. Fluoxetine aims to 
provide essential energy substrates to neurons.13,14 
Although all these processes represent biologically 
plausible targets for neuroprotection, many additional 
patho logical processes can be implicated in disease 
progression, including innate or adaptive mediated inflam­
mation and inadequate remyelination. Thus, several 
explan ations could account for why amiloride, fluoxetine, 
and riluzole did not show efficacy in our study, including 
(but not restricted to) the ultimate relevance of the dynamic 
in­vivo disease processes primarily targeted by these three 
drugs. Indeed, our findings expose our incomplete 
knowledge of the pathobiology of secondary progressive 
multiple sclerosis.
Moreover, although evidence (clinical and MRI) for 
ongoing focal inflammatory disease activity in our study 
cohort was scant, we did not record any B­cell or microglial 
activity. In terms of phase 2 neuroprotection trials showing 
reductions in the rate of brain atrophy of 40–70%, use of 
disease­modifying therapies has been between 0% and 
45%.7,8,30 In view of positive results from the ocrelizumab4 
and siponimod3 phase 3 trials, future work will most 
likely stratify use of anti­inflammatory com pounds in 
conjunc tion with possible neuroprotective agents.
The findings that fluoxetine was associated not only 
with a significantly higher PBVC at 24 weeks compared 
with placebo but also a concomitant decrease in the 
number of new or enlarging T2 lesions at 96 weeks 
should be interpreted with caution. These outcomes 
were secondary outcomes and the number of participants 
developing new or enlarging T2 lesion was, overall, low 
(mean 3·0 [SD 6·9] lesions; median 0 [IQR 0–2]). 
Additionally, the MRI protocol did not include a post­
gadolinium scan at baseline and we were, therefore, 
unable to establish whether some of the patients allocated 
fluoxetine had, by chance, greater ongoing subclinical 
disease inflammatory activity at study entry. A paradoxical 
reduction in parenchymal brain volume compared with 
placebo (pseudoatrophy) has been well described31,35,36 in 
both immunomodulatory (eg, natalizumab)35 and sodium­
channel blockade (eg, lamotrigine)31 studies. Fluoxetine 
might, therefore, exert a degree of immunomodulatory 
activity (eg, decreased lymphocyte proliferation and sup­
pressed interferon­γ production) by acting on astrocytes;37 
findings of a small study showed reduction of new 
enhancing lesions in patients with relapsing­remitting 
multiple sclerosis.38 However, the primary outcome of our 
study at week 96 was negative and accords with the lack 
of therapeutic effect seen in the FLUOX­PMS trial of 
137 patients with progressive multiple sclerosis, which also 
did not show a beneficial effect on brain atrophy in a 
subgroup.39
The MS­SMART trial was restricted to patients with 
secondary progressive multiple sclerosis, with inclusion 
criteria as described. Generalisation to a wider population 
(eg, greater disability, older, or with primary progressive 
disease) is uncertain. Nonetheless, overall, we feel our 
study population will have mostly captured the secondary 
progressive clinical phenotype.
In conclusion, we have shown that a multiarm approach 
can be used successfully to expedite drug discovery in 
patients with progressive multiple sclerosis. Such trial 
designs will be highly relevant to future thera peutic 
develop ment in brain medicine in general. They are 
necessary to confirm or refute postulated pathways and 
give insight into the pathobiology of progressive multiple 
sclerosis. 
Our results do not support the effectiveness of amiloride, 
fluoxetine, and riluzole in reducing disease progression 
for secondary progressive multiple sclerosis, and they 
indicate that exclusive targeting of axonal patho biology 
is an inadequate strategy to achieve neuro protection in 
pro gressive disease. In view of the need to develop 
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disease­modifying treatments for progressive multiple 
sclerosis, this finding challenges the area of research to 
shift towards combinatorial strategies or stratification 
based on greater resolution of relevant pathobiology at the 
level of indi vidual patients.
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